Description
Premarin – estrogen drug. It contains a mixture of naturally occurring equine estrogens (conjugated estrogens), which are similar to endogenous estrogens. In target tissues (organs of the female urogenital system, breast, hypothalamus, pituitary) estrogens penetrate into the cells and binding to estrogen receptors nuclei regulate RNA and protein synthesis, causing metabolic effects.
The drug is easier and relieves climacteric syndrome associated with estrogen deficiency: vasomotor disorders (including hot flashes) and urogenital symptoms (atrophic vaginitis and atrophic urethritis).
Premarin prevents the development of post-menopausal osteoporosis, reduces bone resorption, but does not stimulate bone formation.
The drug increases the level of HDL cholesterol, lowers LDL and total cholesterol levels, thereby reducing the risk of cardiovascular disease.
When using Premarin as replacement therapy in female hypogonadism or primary ovarian failure is noted the appearance of secondary sexual characteristics in patients.
Side effect of Premarin
On the part of the reproductive system: the emergence of bleeding (of varying intensity), a change in the intensity of menstruation, amenorrhea.
From the digestive system: nausea, vomiting, bloating, epigastric pain, cholestatic jaundice, pancreatitis.
From endocrine system: an increase or decrease in body weight, increase in size and tenderness of the breasts, the appearance of secretions from them, changes in libido.
CNS: headache, dizziness, migraine, chorea.
From a sight organ: increased curvature of the cornea.
Dermatologic reactions: melanose (may persist after discontinuation), chloasma, alopecia, rash.
Cardio-vascular system: vein thrombosis, pulmonary thromboembolism.
Other: edema, exacerbation of porphyria.
Application of Premarin
Premarin is used to treat conditions that occur in women during menopause and post-menopause.
- vasomotor disorders of varying severity caused by estrogen deficiency (hot flushes, sweating);
- atrophic vaginitis, atrophic urethritis;
- prevention and treatment of osteoporosis induced by estrogen deficiency;
- reducing the risk of coronary heart disease and associated mortality in postmenopausal women;
- gipoestrogenizm female (female hypogonadism or primary ovarian failure).
